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Objective. Utilizing a food allergy murine model, we have investigated the intrinsic antiallergic potential of the Lactococcus
lactis NCC 2287 strain. Methods. BALB/c mice were sensitized at weekly intervals with ovalbumin (OVA) plus cholera toxin
(CT) by the oral route for 7 weeks. In this model, an oral challenge with a high dose of OVA at the end of the sensitization
period leads to clinical symptoms. Lactococcus lactis NCC 2287 was given to mice via the drinking water during sensitization
(prevention phase) or after sensitization (management phase). Results. Lactococcus lactis NCC 2287 administration to sensitized
mice strikingly reduced allergic manifestations in the management phase upon challenge, when compared to control mice. No
preventive eﬀect was observed with the strain. Lactococcus lactis NCC 2287 signiﬁcantly decreased relative expression levels of the
Th-2 cytokine, IL-13, and associated chemokines CCL11 (eotaxin-1) and CCL17 (TARC) in the ileum. No eﬀect was observed in
the jejunum. Conclusion/Signiﬁcance. These results taken together designate Lactococcus lactis NCC 2287 as a candidate probiotic
strain appropriate in the management of allergic symptoms.
1.Introduction
The prevalence of allergic diseases has been increasing
dramatically in the past decades [1, 2]. Allergic sensitization
starts in early childhood mainly to common food allergens
encountered in everyday food products such as cow’s milk,
eggs, and wheat. Subsequent exposure to the allergen
involves an intricate interplay of cellular components of
the adaptive immune system in which CD4+ T cells are
activated to secrete cytokines such as IL-4, IL-5, and IL-13
[3, 4]. The development of allergic manifestations can be
alteredviatwo approaches,one in whichsensitization to new
allergens is prevented, thereby inhibiting the development
of the Th-2 conditioning [5]. We refer to this approach as
“prevention” in the context of our study. Once sensitization
to the allergenhas occurred, subsequentexposure cantrigger
allergicsymptoms;theeﬀectivemanagementoftheseallergic
manifestations then becomes the primary goal. We have
named this approach “management” in relation to our study.
Probiotics are deﬁned by the WHO as “living micro-
organisms that when administered in adequate amounts
confer a health beneﬁt to the host” [6]. Among potential
health promoting attributes, the capacity of probiotic strains
to modulate the host immune system, either by direct signal-
ing or by modulating the intestinal microbiota, is currently
an area of intense research. The beneﬁcial role of probiotics,2 Clinical and Developmental Immunology
especially Lactobacillus and Biﬁdobacterium strains in atopic
diseases, has been investigated with increasing interest over
the past few years with both animal studies [7, 8]a n d
human clinical trials [9–12]. These studies have yielded
conﬂicting results that in part reﬂect the diversity of clinical
settings studied as well as the diﬀerent probiotic strains that
have been investigated. The importance of intervening at
the appropriate time window in relation to allergies, that
is, either by preventing sensitization or in management of
allergic symptoms, has remained under investigated.
B a s e do ne x t e n s i v ein vitro immune proﬁling of diﬀerent
candidate probiotic strains using both murine and human
cell-based assays, we selected for the current study a lactic
acid bacterial strain Lactococcus lactis (L. lactis) NCC 2287.
We sought to evaluate the beneﬁts of intervening at the two
phases, that is, prevention and management, in a murine
model of food allergy via L. lactis NCC 2287. Lactococcus
strains have been used to deliver therapeutic molecules [13]
but have rarely been individually studied in disease models
for their probiotic eﬀects. We report that while no preventive
eﬀect with the strain was observed, L. lactis NCC 2287
administration to sensitized mice strikingly reduced allergic
scoresinduceduponoralchallengeinthemanagementphase
when compared to control mice. In addition, we investigated
the diﬀerent mechanisms via which L. lactis NCC 2287 may
exertitstherapeuticeﬀect.L.lactisNCC2287administration
during the management phase leads to a decrease in IL-
13 production from restimulated mesenteric lymph node
(MLN) cells along with a signiﬁcant decrease in the relative
expression levels of IL-13 and Th-2 associated chemokines
CCL11 (eotaxin-1) and CCL17 (TARC) in the ileum but not
in the jejunum.
2.MaterialsandMethods
2.1. Reagents and Bacterial Biomass. Lactococcus lactis (L.
lactis) strain NCC 2287 is a dairy starter strain from
the Nestl´ e culture collection (NCC) that was deposited at
Collection Nationale de Cultures de Microorganismes at
Institut Pasteur, Paris, France (CNCM I-4154). Bacterial
biomass was produced by culture of NCC 2287 under
standard conditions. Growth curve was determined for the
strain, and according to this, bacterial cells were harvested by
centrifugation 3h after entering in the stationary phase. The
biomass was washed 2x in cold PBS and frozen in PBS 20%
glycerol at −80◦C.
2.2. OVA Food Allergy Murine Model. All animal studies
were approved by a Nestec internal Ethics Committee and
the Service V´ et´ erinaire of the Canton of Vaud, Switzerland
(Authorization no. 1970). This model has been described in
detail before [14]. Brieﬂy, six-week old conventional female
BALB/c mice (Harlan Laboratories, France) were sensitized
(n = 10 per group; negative control n = 5) orally via
gavage at weekly intervals by 20mg of ovalbumin (OVA)
(Fluka, Buchs, Switzerland) and 10μg/mouse of Cholera
toxin (CT) (List Biologicals, purchased from LuBioscience,
Lucerne, Switzerland) for 7 consecutive weeks. Animals were
challenged orally via gavage with 100mg of OVA one week
after the last sensitization (Figure 1(a)). Starting 30minutes
after challenge, mice were individually observed for 30min.
Clinical symptoms were recorded and quantiﬁed as follows
(allergic score): 0: no symptoms, less than 4 episodes of
scratching; 1: 4–10 episodes of scratching around the nose
and head, no diarrhoea; 2: more than 10 episodes of
scratching or bristled fur and immobility or soft stool; 3:
diarrhoea or laboured respiration or cyanosis; 4: diarrhoea
in combination with immobility after prodding, bristled
fur, laboured respiration or cyanosis; 5: anaphylaxis. Mice
demonstrating a symptom severity of ≥4w e r es a c r i ﬁ c e d
immediately. Four hours afterchallenge,mice were sacriﬁced
afterisoﬂuraneanaesthesiaandterminalbleeding.Bloodand
the last centimetre of ileum and jejunum were taken and
frozen in liquid nitrogen. L. lactis strain NCC 2287 (5 ×
108 CFU/mLindrinkingwater)wasadministeredatdiﬀerent
phases of the experiment and its eﬀect was compared to the
positive (OVA + CT) control groups. To evaluate the eﬃcacy
during the prevention phase, we administered the probiotic
starting 5 days before the ﬁrst oral sensitization. Adminis-
tration was then continued during the entire experimental
period. To assess the eﬀect of administering the probiotic in
sensitized mice, L. lactis NCC 2287 was provided in drinking
water starting after the last sensitization up to the challenge
withOVAforatotaldurationof8days(managementphase).
2.3. Quantiﬁcation of Serum Levels of Mouse Mast-Cell Pro-
tease 1 (MMCP-1). MMCP-1 was analyzed in mouse serum
by ELISA, purchased from Moredun Scientiﬁc (Penicuik,
Scotland) according to the manufacturer’s instructions. The
MMCP-1 concentration was obtained by converting OD
values in pg/mL using a polynomial standard curve.
2.4. Quantiﬁcation of Serum Levels of OVA-Speciﬁc IgE,
IgG1, and IgG2a. OVA-speciﬁc immunoglobulin-E (IgE),
immunoglobulin-G1 (IgG1), and immunoglobulin-G2
(IgG2a) concentrations were measured by ELISA as
described previously [14, 15]. For IgE measurement, plates
(NUNC Maxisorp; VWR, Nyon, Switzerland) were coated
overnight at 4◦C with rat antimouse IgE (2μg/mL; BD
Pharmingen, Allschwil, Switzerland). After washing, wells
were blocked with PBS-1% BSA for 1h at RT. Serially diluted
sera and standard (monoclonal mouse anti-OVA; ABD
Serotec, D¨ usseldorf, Germany) were incubated for 2h at
37◦C. Then, biotinylated-OVA (1μg/mL) was added to the
plate for 1h at 37◦C, followed by incubation with HRP-
labeled streptavidin (1:1000; KPL; Socochim, Lausanne,
Switzerland) for 30min at 37◦C. Plates were developed with
tetramethylbenzidine (TMB) substrate (KPL). The reaction
was stopped with 1M HCl (Merck, Darmstadt, Germany).
Optical densities were measured at 450nm. Concentrations
were calculated by converting OD values in pg/mL using a
polynomial standard curve. For IgG1 and IgG2a, microtiter
plates were coated with OVA (Sigma, Buchs, Switzerland)
(100μg/mL) overnight at 4◦C. Wells were washed with
PBS 0.05% Tween (Biorad, Reinach, Switzerland) and then
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Figure 1: L. lactis NCC 2287 alleviates allergic symptoms in sensitized mice. L. lactis NCC 2287 (5 × 108 CFU/mL) was given ad libitum
to mice (n = 10, n = 5 in Neg. control) orally via drinking water (a). Administration was either before the ﬁrst sensitization and given
throughout the experiment (prevention phase) or in the one week after the last sensitization (management phase). After challenge, mice
treated with L. lactis NCC 2287 in the management phase (dark grey bar graph) developed signiﬁcantly reduced clinical scores than
sensitized, untreated animals in the positive control group (white bar graph). Mice consuming L. lactis NCC 2287 during the prevention
phase of the experiment (grey bar graph) did not exhibit reduced symptoms. An exploratory experiment 1 (left panel) and a conﬁrmatory
experiment 2 (right panel) are shown. 3 experiments were performed in total (b).
Serially diluted standard (monoclonal mouse anti-OVA IgG1
and anti-OVA IgG2a from Antibody Shop; LucernaChem,
Lucerne, Switzerland) and serum samples were incubated
for 2h at 37◦C, followed by incubation for 2h with a HRP-
labelled goat antimouse IgG1 or IgG2a antibody (1:5000;
Southern Biotech; Bioconcept, Allschwil, Switzerland).
Plates were then developed, read, and analyzed.
2.5. Isolation and Culture of MLN Cells. Mesenteric lymph
nodes (MLN) were homogenized with a syringe plunger in
a cell strainer (BD Falcon; Milian, Meyrin, Switzerland).
Cells were centrifuged and washed 2x in RPMI medium
(Sigma) complemented with 10% fetal bovine serum (FBS;
Bioconcept, Paris, France), 1% L-glutamine (Sigma), 1%
Penicillin/Streptomycin (Sigma), 0.1% Gentamycin (Sigma),
50μM β-mercaptoethanol (Sigma). Cells (3 × 105 cells/well)
were cultured in 96 well ﬂat bottom plates (Corning,
Milian, Meyrin, Switzerland) in the absence or presence of
OVA (1mg/mL). After 72hrs of culture, plates (including
supernatant and cells) were frozen at −20◦C.
2.6. Quantiﬁcation of Cytokines in Culture Supernatant Fluid.
Mouse IL-4, IL-5, and IL-10 were measured using the mouse
Th-1/Th-2 multiplex kit (Meso Scale Discovery, Gaithers-
burg, Md, USA) according to the manufacturer’s instruc-
tions. IL-13 was measured using a Mouse IL-13 (DY413E)
ELISA kit from R&D Systems (Abington, England).
2.7.QuantitativeGeneExpressionLevelsbyLow-DensityArray
(LDA). Total ribonucleic acids (RNAs) from ileum and
jejunum were extracted according to the manufacturer’s pro-
tocol using the SV Total RNA Isolation System kit (Promega,
D¨ ubendorf,Switzerland).RNAwasquantiﬁedwithquant-IT
RibogreenReagentkitpurchasedfromPromegaaccordingto4 Clinical and Developmental Immunology
the manufacturer’s protocol. Reverse transcription was per-
formedon1μgoftotalRNAbyusingtheMultiscribeReverse
Transcriptase kit (Applied Biosystems, Foster City, Calif,
USA). Total RNA was mixed with 50μMo fr a n d o mh e x -
amers, 0.5mM of dNTPs, 20U of RNase inhibitor (Applied
Biosystems), 62.5U of Multiscribe reverse transcriptase, 1X
RT buﬀer, and 5.5mM of MgCl2 in a ﬁnal volume of 50μL.
Reverse transcription was performed on a T3 thermocycler
(Biometra, G¨ ottingen, Germany) with the following cycle
program: 10min at 25◦C, 30min at 48◦C, 5min at 95◦C
to ﬁnish at 4◦C. Low-density arrays were designed online
on the Applied Biosystems website. The load and the run
were performed according to the manufacturer’s protocol on
a quantitative ABI-Prism 7900HT. The quantiﬁcation was
normalized with the mean of 3 house-keeping genes: β-
actin, GAPDH, and HPRT. The Ct value for each gene was
correctedbythe Ct mean of thesethree house-keeping genes.
Based on the cycle threshold (Ct) values obtained, a relative
and normalized mRNA expression was determined for each
gene using the ΔCt. The results were calculated as a relative
expression using the formula 2−ΔCt × K,w h e r eK is a 106
factor. Fold increase results expression was normalized to
expression levels in the negative control group.
2.8.StatisticalAnalyses. ThesoftwareR2.2.1wasusedforthe
analyses. Clinical scores were evaluated using the Kruskal-
Wallis tests, followed by Wilcoxon test. All other outcomes
were treated with Kruskal-Wallis followed by Wilcoxon test.
Corrections were applied following the Bonferroni-Sidak
procedure. Statistical test to compute P values are calculated
for median ± SEMedian values. Results were considered as
signiﬁcant with a P value ≤ 0.05.
3. Results
3.1. L. lactis NCC 2287 Oral Administration Is Eﬀective in the
ManagementofFoodAllergySymptomsbuthasnoEﬀectonthe
PreventionofSensitization. TheinvivoeﬀectofL.lactisNCC
2287 was tested in a murine model of food allergy in the pre-
vention of allergic sensitization as well as in the management
ofallergicsymptomsinsensitizedmice(Figure 1(a)).Forthis
purpose, BALB/c mice were sensitized to OVA via the oral
route and challenged as described in Section 2. L. lactis NCC
2287 was given to mice via drinking water (5 × 108 CFU/mL;
ad libitum) during the prevention phase (5 days before the
ﬁrst sensitization until the end of the experiment) or in the
last week of the experiment following the last sensitization
(day 43–49; management phase). Figure 1(b) illustrates the
clinical symptoms observed in diﬀerent groups of mice in
two representative experiments. After challenge, animals in
the positive control group developed statistically signiﬁcant
clinical scores of food allergy compared to the negative
control group (clinical score of 1.9 ± 0.3 versus 0.5 ± 0.17;
P<0.008 in exploratory experiment 1 and clinical score
of 2.5 ± 0.31 versus 0.4 ± 0.16; P<0.001 in conﬁrmatory
experiment 2). Sensitized mice treated with L. lactis NCC
2287 in the management phase developed less severe clinical
symptoms than the positive control group (0.9 ± 0.26; P =
0.08 in exploratory experiment 1 and 1.3 ± 0.37; P = 0.038
in conﬁrmatory experiment 2). However, mice consuming L.
lactis NCC 2287 strain during the prevention phase of the
experiment did not exhibit signiﬁcantly reduced symptoms
upon OVA challenge (2.4 ± 0.37; P = 0.97 in exploratory
experiment 1 and 1.7 ± 0.42; P = 0.18 in conﬁrmatory
experiment 2). These ﬁndings suggest that L. lactis NCC
2287 strain acts more likely during the management phase
following challenge and not during the prevention phase.
3.2. L. lactis NCC 2287 Administration Does Not Inﬂuence
Levels of OVA-Speciﬁc IgE, IgG1, or Mouse Mast-Cell Protease-
1(MMCP-1)inSensitizedMice. Inordertodeterminewhich
immunological parameters contributed to the observed ben-
eﬁcialeﬀectofL.lactisNCC2287onclinicalscores,weinves-
tigated the impact on serum levels of mouse mast-cell pro-
tease 1 (MMCP-1) and OVA-speciﬁc antibodies (IgE, IgG1,
and IgG2a). MMCP-1 levels were increased signiﬁcantly in
the positive control group of animals (1107 ± 322pg/mL)
when compared to negative control, nonsensitized mice
(3.8 ± 2.2pg/mL; P ≤ 0.001). Administration of L. lactis
NCC 2287 did not statistically decrease MMCP-1 in either
the preventive (2113 ± 521pg/mL; P = 0.17) or the
management (773 ± 298pg/mL; P = 0.48) phases of
the model (Figure 2(a)). OVA-speciﬁc IgE (Figure 2(b)),
IgG1 (Figure 2(c)), and IgG2a (Figure 2(d)) levels increased
signiﬁcantlyinthepositivecontrolgroup(1674 ±551pg/mL
for IgE, 535 ± 192pg/mL for IgG1 and 6058 + 3474pg/mL
for IgG2a) when compared to the negative control group
(19 ± 11pg/mL for IgE and below detection level for IgG1
and IgG2a; P ≤ 0.001). However, the administration of
L. lactis NCC 2287 did not signiﬁcantly impact the levels
of the immunoglobulin subtypes, neither in prevention
(2986 ± 661pg/mL for IgE, 857 ± 221pg/mL for IgG1 and
5603 + 1306pg/mL for IgG2a; P ≥ 0.1) or in symptom
management (2054 ± 1281pg/mL for IgE, 558 ± 238pg/mL
for IgG1 and 8045 ± 5951pg/mL for IgG2a; P ≥ 0.3) phases
of the model (Figures 2(b)–2(d)). These data suggest that L.
lactis NCC 2287 is unlikely to lead to a reduction in allergic
scores via its eﬀect on two pathways commonly involved in
theallergiccascade,namely,mastcellactivationandhumoral
immunity.
3.3. Impact of Administering L. lactis NCC 2287 during
Management Phase on IL-13 Production by MLN Cells. To
further identify potential mechanisms via which L. lactis
NCC 2287 exerted its beneﬁcial eﬀect, we next evaluated the
ex vivo cytokine proﬁle of antigen-restimulated lymphocytes
isolated from the MLN. As shown in Figure 3,M L Nc e l l s
from the negative control group secreted low levels of Th-
2 cytokines (IL-4, IL-5, IL-10, and IL-13). In compari-
son, MLN cells from the positive control group secreted
increased levels of IL-4 (Figure 3(a)), IL-5 (Figure 3(b)), IL-
10 (Figure 3(c)), and IL-13 (Figure 3(d)). MLN cells from
mice administered L. lactis NCC 2287 during the prevention
phase exhibited similar levels of Th-2 cytokines as the
positive control group. Of interest were the MLN cells of
mice given L. lactis NCC 2287 during the managementClinical and Developmental Immunology 5
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Figure 2: MMCP-1 (a), OVA-speciﬁc IgE (b), IgG1 (c), and IgG2a (d) levels in the serum 4 hours after challenge. Results from the
conﬁrmatory experiment are shown. OVA-speciﬁc levels of IgE, IgG1, and IgG2a were increased signiﬁcantly in positive control mice
compared to the negative control group. Administration of NCC 2287 both in the prevention and management phases did not signiﬁcantly
reduce levels of MMCP-1 and OVA-speciﬁc IgE, IgG1, and IgG2a. No eﬀect of L. lactis NCC 2287 on mast cells and immunoglobulins.
phase that demonstrated a trend to decreased IL-13 cytokine
production (P = 0.08) but not IL-4, IL-5, and IL-10 levels
compared to the positive control.
3.4. L. lactis NCC 2287 Administration during Management
Phase Reduced Relative Gene Expression Levels of the Th-
2 Cytokine IL-13 in the Ileum but not in the Jejunum of
Sensitized Mice. To correlate the results obtained ex vivo
with OVA restimulation on IL-13, we investigated gene
expression levels of IL-13, locally in the gastrointestinal
tract. In addition, we also examined the expression of the
IL-5 encoding gene. For this purpose, we isolated tissue
samples from ileum and jejunum and examined relative gene
expression levels by RT-PCR. IL-5 gene expression showed
an increased trend in the ileum of positive control mice
when compared to the negative control group (726 ± 403 in
positivecontrolversus55 ±47innegativecontrol;P<0.08).
The administration of L. lactis NCC 2287 in sensitized mice
resulted in lower relative expression levels of IL-5 in the
ileum (177 ± 95; P = 0.1 when compared to the positive
control group); however, this eﬀect was not statistically
signiﬁcant. There was no impact on IL-5 gene expression6 Clinical and Developmental Immunology
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Figure 3: Decreased IL-13 production from restimulated MLN cells in mice administered L. lactis NCC 2287 in the management phase.
IL-4 (a), IL-5 (b), IL-10 (c), and IL-13 (d) levels in the supernatants of MLN cells restimulated ex vivo with OVA. Positive control group
secreted increased levels of Th-2 cytokines. MLN cells from mice administered L. lactis NCC 2287 during the prevention phase exhibited
similar levels of Th-2 cytokines as the positive control group. MLN cells of mice administered L. lactis NCC 2287 during the management
phase produced decreased levels of IL-13 cytokine levels but not IL-4, IL-5, or IL-10.
levels in the jejunum (Figure 4(a)). IL-13 gene expression
levels on the other hand were remarkably increased in the
ileum (992.6 ± 360.2 in positive control versus 7.3 ± 1.2 in
negative control; P ≤ 0.01). Interestingly, the administration
of L. lactis NCC 2287 strongly mitigated the increase in the
relative gene expression level for IL-13 (124 ± 62; P = 0.015
when compared to the positive control group) in the ileum
of sensitized mice following challenge. There was no eﬀect
on IL-13 relative gene expression in the jejunum of mice
administered L. lactis NCC 2287 during the management
phase (Figure 4(b)).
3.5. Decreased Th-2 Chemokines CCL11 (Eotaxin-1) and
CCL17 (TARC) Gene Expression Levels in the Ileum Following
L. lactis NCC 2287 Administration during the Management
Phase. Chemokines associated with allergic disorders and
upregulated in the presence of elevated levels of IL-13 such
as CCL11 (eotaxin-1) and CCL17 (TARC) were analyzed.
Sensitization and subsequent challenge resulted in a sig-
niﬁcant increase in the relative gene expression levels of
the chemokine CCL11 (eotaxin-1) in the ileum of positive
control mice in comparison to the negative control group
(24904 ± 6797 versus 7809 ± 3286 in negative control;
P = 0.006; Figure 5(a)). A similar statistically signiﬁcant up-
regulation was also observed on the relative gene expression
levels of CCL17 in the positive control group (3943 ± 888
versus400 ±177innegativecontrol;P = 0.001;Figure 5(b)).
TheadministrationofL.lactisNCC2287inthemanagement
phase signiﬁcantly reduced the relative gene expression levels
of both CCL11 (5172 ± 1341; P = 0.002 versus positiveClinical and Developmental Immunology 7
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Figure 4: L.lactisNCC 2287 downregulates IL-13 expression in the ileum but not in thejejunum of sensitized mice. Relative gene expression
of IL-5 (a) and IL-13 (b) in samples from ileum and jejunum analyzed by low-density arrays. Sensitization followed by challenge led to
upregulation of IL-5 (P = 0.08) and IL-13 (P = 0.001) mRNA in the positive control group compared to the negative control in the ileum.
Administration of NCC 2287 in the management phase led to a marked downregulation of IL-13 expression in the ileum (P = 0.015) but
not in the jejunum.
control group) and CCL17 (1716 ± 521; P = 0.04 versus
positive control group). Similarly, as observed for IL-13,
no eﬀect on CCL11 or CCL17 gene expression levels was
observed in other intestinal sites such as jejunum.
4. Discussion
The current study explored the potential eﬃcacy and
mechanism of action of L. lactis NCC 2287 against the
development of food allergy manifestations. Speciﬁcally, we
delineated the eﬃcacy of this strain in two critical phases
of a food allergy mouse model, namely, by intervention
during the sensitization phase (prevention phase) and in
the symptomatic phase by intervention in sensitized mice
shortly before challenge with the objective to manage allergic
symptoms (management phase). When administered in vivo,
L. lactis NCC 2287 signiﬁcantly reduced food allergic symp-
toms in sensitized mice. Interestingly, the administration
of the strain during sensitization was without any eﬀect
(Figure 1(b)). This underlines that certain probiotic strains
may be “specialized” in modulating diﬀerent phases of the
allergic response. This is one of the most important ﬁndings
of the current study and underlines that the eﬃcacy of
probiotic interventions is strongly dependent on the speciﬁc
strain(s) used, of the clinical indication for which the strain
is applied and the appropriate timing of the intervention.8 Clinical and Developmental Immunology
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Figure 5: L. lactis NCC 2287 administration to sensitized mice downregulates Th-2 chemokines CCL11 (eotaxin-1) and CCL17 (TARC)
in the ileum but not in the jejunum. Relative gene expression for CCL11 (a) and CCL17 (b) in samples from ileum and jejunum analyzed
by low-density arrays. Sensitization followed by challenge led to upregulation of CCL11 (P = 0.006) and IL-13 (P = 0.001) mRNA in the
positivecontrolgroupcomparedtothenegativecontrolintheileum.AdministrationofNCC2287inthemanagementphaseledtoamarked
downregulation of both CCL11 (P = 0.002) and CCL17 expression (P = 0.04) in the ileum but not in the jejunum.
The reduction of symptoms following L. lactis NCC 2287
administration in the management phase was not associated
in the studied animal model with a reduction in levels of
OVA-speciﬁc antibodies associated with a Th-2 phenotype,
that is, IgE, IgG1, and IgG2a (Figures 2(b)–2(d)). These
results are not completely surprising, since the levels of
antigen speciﬁc immunoglobulins build up over time with
repeated sensitizations, leading to a long-term persistence of
memory B cells. Previous studies have also reported similar
results upon the administration of probiotics in diﬀerent
allergy models [16, 17]. As we had previously observed an
association between decreased MMCP-1 levels, a marker
for mast cell activation and reduced allergic scores with
a nutritional intervention in the same animal model [15],
we also evaluated this parameter in the present study; the
strain did not impact the levels of MMCP-1. It is then likely
that mechanistically the antiallergic eﬀect of this strain is
not mediated by direct inhibition of mast-cell degranula-
tion. Indeed, conﬁrmatory in vitro experiments with IgE-
sensitized RBL cells also did not support an inhibitory eﬀect
of L. lactis NCC 2287 on mediator release (data not shown).
In our model, the reduction in clinical scores in the man-
agement phase was paralleled by a decrease in the secretion
of IL-13 by OVA restimulated MLN cells (Figure 3(d))b u t
not in IL-4, IL-5, or IL-10 (Figures 3(a)–3(c)). IL-13 is a vital
Th-2 cytokine that dominates the chronic phase of allergicClinical and Developmental Immunology 9
sensitization and is primarily involved in the recruitment
of eosinophils to sites of allergic inﬂammation and their
subsequent activation and survival at these inﬂammatory
sites [18, 19]. IL-13 is secreted by a variety of immune cells
such as Th-2 cells, mast cells, dendritic cells, and eosinophils
[20, 21]. IL-13 has been closely linked to the pathogenesis
of a food allergic disorder, eosinophilic esophagitis both in
animal studies and in clinical samples obtained from indi-
viduals with allergic disorder [22, 23]. IL-13 is also closely
related to another well-studied Th-2 cytokine, IL-4 with
respect to structure and function as both cytokines share
a common receptor (IL-4Rα)[ 24, 25] .W h i l er e l a t i v eg e n e
expression levels of IL-4 were undetectable, we examined
expression patterns of IL-5 and IL-13 following L. lactis NCC
2287 administration (Figure 4). There was nearly a 10-fold
reduction in the relative gene expression of IL-13 in the
ileum. This dramatic reduction was not observed elsewhere
in the gastrointestinal tract, that is, jejunum (Figure 4).
These results are also in line with our previous observations
invitrowithL.lactisNCC2287inassaysincluding monocyte
derivedDCs-restingCD4+TcellcoculturesandTh-2skewed
PBMC stimulation. L. lactis NCC 2287 was selected for
its potential Th1/Treg immunomodulatory proﬁle and its
ability to inhibit the levels of Th2 cytokines in particular IL-
5 and IL-13 (unpublished). These are intriguing results and
suggest a mechanism whereby L. lactis NCC 2287 exerts its
probiotic eﬀect at a speciﬁc site of localized inﬂammation.
Supporting the local reduction of IL-13, we observed a
statistically signiﬁcant decrease in relative gene expression
levels of Th-2 associated chemokines mainly CCL11 and
CCL17 (Figures 5(a) and 5(b)). These chemokines and par-
ticularlyCCL11(eotaxin-1),arecriticallylinkeddownstream
to IL-13 signaling [26–28]. CCL17 (TARC) has previously
been reported to be associated with allergic disorders [29]
and potentially altered by probiotics in in vitro systems
mimicking allergic pathogenesis [30]. The reduction of
CCL11 and CCL17 expression was also observed only in
the ileum further providing support to this site being an
“active”siteofinﬂammationinagastrointestinalfoodallergy
immune response as well as a site of action of L. lactis NCC
2287.
Multiple biological pathways exist that can contribute
to the regulation of an aberrant immune response as is the
case with food allergies. We have identiﬁed in this study
one of the many mechanisms that could be responsible for
the initiation of food allergic symptoms, mainly increased
levels of IL-13 locally in the ileum and its downregulation
upon administration of a probiotic L. lactis NCC 2287 in
the management phase. The fact that the probiotic eﬀect
was observed for the strain only in sensitized mice suggests
that L. lactis NCC 2287 acts speciﬁcally at sites of allergic
inﬂammation. The survival rate and physiology of L. lactis
in the digestive tract have previously been studied. In these
observations, the L. lactis strain MG 1363 was reported to
have a higher survival rate in the ileum in rodents [31].
These studies raise the possibility that in the mouse model
used in this study, a similar preferential localization of the
strain can happen in the ileum upon oral administration.
Given such a scenario, the strain would then indeed have the
maximum impact during the challenge phase of the model
in the ileum. It would be interesting to study the eﬀect of L.
lactis NCC 2287 in either diﬀerent models of allergy (skin
and respiratory) and to compare the eﬀect to other L. lactis
strains. This approach of studying a bacterial strain for its
probiotic eﬀect in diﬀerent phases of a disease model is the
“way forward” for a more rational and practical approach
to the selection of diﬀerent strains for a particular health
beneﬁt.
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